Tuberculosis and viral hepatitis infection in Eastern Europe, Asia, and Latin America: impact of tumor necrosis factor-α inhibitors in clinical practice

por Chen YH, Carvalho HMS, Kalyoncu U, Llamado LJQ, Solano G, Pedersen R, Lukina G, Lichauco JJ, Vasilescu RS
Publicado 2018

Predicting New Anti-Norovirus Inhibitor With the Help of Machine Learning Algorithms and Molecular Dynamics Simulation–Based Model

por Oluwakemi Ebenezer, Nkululeko Damoyi, Michael Shapi
Publicado 2021

EPIDEMIOLOGICAL CHARACTERISTIC OF VIRAL HEPATITIS B AND C IN THE HEMODIALYSIS UNITS IN SAINT-PETERSBURG IN MODERN TIME. Part 1. Registration of hemo-contact viral hepatitis and ser...

por S. L. Mukomolov, I. A. Levakova, E. V. Sinaiskaya, L. G. Suliagina, P. N. Kisliy, G. J. Timakhovskaya, N. V. Ivanova, K. G. Staroselskiy, V. J. Ryasnianskiy
Publicado 2014

EXPRESSION PATTERNS OF CHEMOKINE RECEPTORS CXCR3 AND CCR6, AND THEIR LIGANDS IN PERIPHERAL BLOOD OF PATIENTS WITH CHRONIC HEPATITIS C DURING ANTIVIRAL THERAPY USING PEGYLATED INTERFERONS

por V. V. Basina, N. A. Arsentieva, O. K. Batsunov, N. E. Lyubimova, A. V. Semenov, E. V. Esaulenko, Areg A. Totolian
Publicado 2019

The PNPLA3 rs738409 148M/M genotype is a risk factor for liver cancer in alcoholic cirrhosis but shows no or weak association in hepatitis C cirrhosis.

por Hans Dieter Nischalke, Cordula Berger, Carolin Luda, Thomas Berg, Tobias Müller, Frank Grünhage, Frank Lammert, Martin Coenen, Benjamin Krämer, Christian Körner, Natascha Vidovic, Johannes Oldenburg, Jacob Nattermann, Tilman Sauerbruch, Ulrich Spengler
Publicado 2011

Erratum for Lowey et al., “Hepatitis C Virus Infection Induces Hepatic Expression of NF-κB-Inducing Kinase and Lipogenesis by Downregulating miR-122”

por Brianna Lowey, Laura Hertz, Stephan Chiu, Kristin Valdez, Qisheng Li, T. Jake Liang
Publicado 2019

The CXCR3(+)CD56Bright phenotype characterizes a distinct NK cell subset with anti-fibrotic potential that shows dys-regulated activity in hepatitis C.

por Marianne Eisenhardt, Andreas Glässner, Benjamin Krämer, Christian Körner, Bernhard Sibbing, Pavlos Kokordelis, Hans Dieter Nischalke, Tilman Sauerbruch, Ulrich Spengler, Jacob Nattermann
Publicado 2012

Hepatitis C virus E2 protein encapsulation into poly D, L-lactic-co-glycolide microspheres could induce mice cytotoxic T-cell response

por Roopngam P, Liu K, Mei L, Zheng Y, Zhu X, Tsai HI, Huang L
Publicado 2016

IFNL4 ss469415590 variant shows similar performance to rs12979860 as predictor of response to treatment against Hepatitis C Virus genotype 1 or 4 in Caucasians.

por Luis M Real, Karin Neukam, Rocío Herrero, Josep M Guardiola, Thomas Reiberger, Antonio Rivero-Juarez, Juliana Salazar, Mattias Mandorfer, Dolores Merino, Vicente Soriano, Antonio Rivero, Juan Macías, Juan A Pineda, Antonio Caruz
Publicado 2014

Assessment of Left Ventricular Systolic Function by Speckle Tracking in Diabetic Patients Receiving Direct Acting Antiviral Drugs for Chronic HCV

por Wael Hassib, Mohamed Abd Elraouf, Reda Biomy, Mohammed Hamouda, Mohamed Mohamed
Publicado 2021

Effect of Successful Direct Acting Antivirals Therapy on Liver Stiffness in Patients with Chronic HCV Infection

por Ibrahim Anam Ezzelregal, Fathya Mostafa Elraie, Khalid Elmola, Mostafa Mohamed Shaqueer
Publicado 2020

EXTRACELLULAR MATRIX CONDITION IN CASE OF HCVASSOCIATED LIVER FIBROSIS

por I. S. Gorelova, L. F. Sklyar, E. V. Markelova, A. I. Simakova, I. V. Zenin
Publicado 2017

PHENOTYPE AND FUNCTIONS OF DENDRITIC CELLS IN PATIENTS WITH CHRONIC VIRAL HEPATITIS

por O. Yu. Leplina, M. A. Tikhonova, A. E. Borisova, N. M. Starostina, A. A. Ostanin, E. R. Chernykh, V. A. Kozlov
Publicado 2014

‘Real-life’ experience with direct-acting antiviral agents for HCV after kidney transplant

por Fabrizio Fabrizi, Cristina Alonso, Ana Palazzo, Margarita Anders, Maria Virginia Reggiardo, Hugo Cheinquer, Maria Grazia Videla Zuain, Sebastian Figueroa, Manuel Mendizabal, Marcelo Silva, Ezequiel Ridruejo
Publicado 2021

Avoiding Drug Resistance by Substrate Envelope-Guided Design: Toward Potent and Robust HCV NS3/4A Protease Inhibitors

por Ashley N. Matthew, Jacqueto Zephyr, Desaboini Nageswara Rao, Mina Henes, Wasih Kamran, Klajdi Kosovrasti, Adam K. Hedger, Gordon J. Lockbaum, Jennifer Timm, Akbar Ali, Nese Kurt Yilmaz, Celia A. Schiffer
Publicado 2020

Possible acute rejection associated with the use of the new antihepatitis C virus medications

por Khaled Ar Karkout, Saleema Al Sherif, Qutaiba Hussein, Alia Albawardi, Yousef Boobes
Publicado 2019

Efficacy and safety of sofosbuvir-based therapies in patients with advanced liver disease in a real-life cohort

por Kutala BK, Mouri F, Castelnau C, Bouton V, Giuily N, Boyer N, Asselah T, Marcellin P
Publicado 2017

EPIDEMIOLOGICAL CHARACTERISTICS OF CHRONIC VIRAL HEPATITIS IN THE RUSSIAN FEDERATION IN 1999–2009

por S. L. Mukomolov, I. A. Levakova
Publicado 2014

Relationships Between Vitamin D Status and Cytokine: Results from Interferon-Based Therapy in Non-Cirrhotic, Treatment-Naïve Patients with Chronic Hepatitis C Infection

por Chen HW, Chiu YL, Hsieh TY, Chen PJ, Huang TY, Lin HH, Shih YL, Lin JC
Publicado 2020

Low frequency of NS5A relevant resistance-associated substitutions to Elbasvir among hepatitis C virus genotype 1a in Spain: a cross-sectional study

por Claudia Palladino, Marta Sánchez-Carrillo, Irene Mate-Cano, Sonia Vázquez-Morón, Ma Ángeles Jimenez-Sousa, Mónica Gutiérrez-Rivas, Salvador Resino, Verónica Briz
Publicado 2017